Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
29,816,999
-
Shares change
-
-1,227,917
-
Total reported value, excl. options
-
$120,746,000
-
Value change
-
-$7,125,584
-
Number of buys
-
14
-
Number of sells
-
-21
-
Price
-
$4.05
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2016
50 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q4 2016.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29,816,999 shares
of 1,571,428,571 outstanding shares and own 1.9% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (9,880,999 shares), FMR LLC (7,065,180 shares), Capital World Investors (4,480,486 shares), BAILLIE GIFFORD & CO (920,984 shares), FIL Ltd (753,741 shares), ORBIMED ADVISORS LLC (724,184 shares), Rock Springs Capital Management LP (675,000 shares), MILLENNIUM MANAGEMENT LLC (671,660 shares), QVT Financial LP (657,258 shares), and Tekla Capital Management LLC (566,368 shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.